SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory
SEQENS, an integrated leader in the manufacturing of active ingredients and pharmaceutical intermediates, announced a multi-million-dollar investment in its research and development laboratory located...
Germany Signs Vaccine Deals To Prepare For Future Outbreaks
BioNTech and CureVac, two German mRNA companies, have agreed to offer Germany with vaccines for future medical catastrophes for the next many years. Reuters...
Pharma Giants Withdraw From Russia Owing To Ukraine Invasion
Hundreds of businesses have announced a suspension or withdrawal of operations in Russia since its invasion of Ukraine. Some of the most recent companies to...
AstraZeneca Makes Advances In Fight Against Ovarian Cancer
Only about half of women infected with ovarian cancer survive five years after diagnosis. AstraZeneca is partnering with a group of doctors and a...
Current COVID-19 Vaccine Trial Scenario For Kids Below 5
After the US Food and Drug Administration postponed essential steps toward legalising COVID-19 vaccinations for children under the age of five by a month,...
NHS New Drug For Blood Cancer To Extend Life By Two Years
Thanks to a deal reached by NHS England, a targeted new medicine for a rare and severe form of lung cancer will be accessible...
Lynparza From AZ As Breast Cancer Cure Gets FDA Approval
The FDA approved the AstraZeneca and Merck medications for a select subset of individuals with severe early-stage breast cancer, after chemotherapy before or after surgery....
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...